Benchtop Cell Sorter Validated in Biosafety Containment Setting
|
By LabMedica International staff writers Posted on 27 Dec 2021 |

Image: The MACSQuant Tyto Cell Sorter can be used safely in at BSL-3 laboratory facilities (Photo courtesy of Miltenyi Biotec)
Fluorescent-activated cell sorting (FACS) is often the most appropriate technique to obtain pure populations of a cell type of interest for downstream analysis. The ability to sort pure populations of immune cells is a critical tool for immunologists.
Aerosol droplets can be generated during the sort, which poses a biosafety risk when working with samples containing risk group 3 pathogens such as Francisella tularensis, Mycobacterium tuberculosis, Yersinia pestis, and severe acute respiratory syndrome coronavirus 2.
Pulmonary pathogen specialists at the Rocky Mountain Laboratories (Hamilton, MT, USA) performed aerosol testing as part of the biosafety evaluation of the MACSQuant Tyto (Miltenyi Biotec, Bergisch Gladbach, Germany) a completely closed, cartridge-based cell sorter. They also established quality control procedures to routinely evaluate instrument performance. Aerosol testing was performed on FACSAria II (BD Biosciences, San Diego, CA, USA) with the Aerosol Management System disabled as a positive control for aerosol generation.
The scientists reported that before usage of the Tyto on the benchtop to sort cells at BSL-3, it was necessary to empirically determine if aerosols were generated during the cell sort procedure. They utilized a novel method using internally fluorescent 1.0 μm beads to perform aerosol testing on the Tyto. These beads were uniform in size and intensely fluorescent in the fluorescein isothiocyanate (FITC) channel.
As a positive control, they detected aerosols generated by the in-house FACSAria II when the Aerosol Management System was disabled, and the flow stream disrupted. As expected, beads were detected on the coverslip after only a 30-second exposure. The MACSQuant Tyto did not produce aerosols as part of the sort procedure. The scientists established a purity of >96%, depletion yield of >80%, and sort efficiency of >85% as benchmarks that must be met during quality control testing.
The authors concluded that they utilized the Tyto cell sorter in their BSL-3 laboratory. This instrument not only has a small footprint but most importantly does not generate aerosols during the sort procedure. The use of this technology will improve current immunological studies in containment laboratories by allowing a greater number of scientific groups to isolate cell types involved in the immune response to high-consequence pathogens for downstream applications. The study was published on November 24, 2021 in the journal Applied Biosafety.
Related Links:
Rocky Mountain Laboratories
Miltenyi Biotec
BD Biosciences
Aerosol droplets can be generated during the sort, which poses a biosafety risk when working with samples containing risk group 3 pathogens such as Francisella tularensis, Mycobacterium tuberculosis, Yersinia pestis, and severe acute respiratory syndrome coronavirus 2.
Pulmonary pathogen specialists at the Rocky Mountain Laboratories (Hamilton, MT, USA) performed aerosol testing as part of the biosafety evaluation of the MACSQuant Tyto (Miltenyi Biotec, Bergisch Gladbach, Germany) a completely closed, cartridge-based cell sorter. They also established quality control procedures to routinely evaluate instrument performance. Aerosol testing was performed on FACSAria II (BD Biosciences, San Diego, CA, USA) with the Aerosol Management System disabled as a positive control for aerosol generation.
The scientists reported that before usage of the Tyto on the benchtop to sort cells at BSL-3, it was necessary to empirically determine if aerosols were generated during the cell sort procedure. They utilized a novel method using internally fluorescent 1.0 μm beads to perform aerosol testing on the Tyto. These beads were uniform in size and intensely fluorescent in the fluorescein isothiocyanate (FITC) channel.
As a positive control, they detected aerosols generated by the in-house FACSAria II when the Aerosol Management System was disabled, and the flow stream disrupted. As expected, beads were detected on the coverslip after only a 30-second exposure. The MACSQuant Tyto did not produce aerosols as part of the sort procedure. The scientists established a purity of >96%, depletion yield of >80%, and sort efficiency of >85% as benchmarks that must be met during quality control testing.
The authors concluded that they utilized the Tyto cell sorter in their BSL-3 laboratory. This instrument not only has a small footprint but most importantly does not generate aerosols during the sort procedure. The use of this technology will improve current immunological studies in containment laboratories by allowing a greater number of scientific groups to isolate cell types involved in the immune response to high-consequence pathogens for downstream applications. The study was published on November 24, 2021 in the journal Applied Biosafety.
Related Links:
Rocky Mountain Laboratories
Miltenyi Biotec
BD Biosciences
Latest Technology News
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Channels
Clinical Chemistry
view channel
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read moreMolecular Diagnostics
view channel
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
New Rapid Ebola Antigen Test Detects Infection at Point of Care
A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda.... Read more
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read moreIndustry
view channel
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








